Clearmind Medicine Receives IRB Approval for Phase 1/2a Trial of CMND-100

Clearmind Medicine has received IRB approval from Tel Aviv Sourasky Medical Center for its Phase 1/2a clinical trial evaluating CMND-100 for AUD treatment. This approval enables patient enrollment at TASMC, a leading clinical site in Israel, prior to commencing the trial at other sites such as Yale School of Medicine and Johns Hopkins University School of Medicine. The study aims to assess the efficacy and safety of CMND-100 in treating AUD.